← GSK overview

GSK vs UK Pound Sterling/US Dollar FX Spot Rate: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

GSK plc (GSK.LSE)

Q3 2026
▲2▼2

GSK's new drug wins offset pipeline setbacks and legal risks

  • FDA approval of Jiditro and other regulatory wins GSK won FDA approval for Jiditro, its first lung cancer drug, plus regulatory nods for Jemperli and Hibsago. These expand GSK's oncology and specialty portfolios, offering new sales streams.

    New drug approvals are major positive catalysts for future revenue.

  • Strong Q2 results and cost-savings plan GSK reported 5% sales growth in Q2, raised full-year guidance, and announced a £1.9bn cost-savings plan. Specialty Medicines grew 14%, showing core business strength and efficiency gains.

    Financial performance and cost cuts directly boost investor confidence.

  • Pipeline setback and legal threat GSK dropped camlipixant, a potential £2.5bn product, and faces AnaptysBio's lawsuit over Jemperli rights. These create uncertainty about future revenue and legal costs.

    Pipeline failures and litigation are key negative drivers for the stock.

  • Competition and patent cliff concerns Moderna's mRNA flu vaccine challenges GSK's flu franchise, and the dolutegravir HIV patent cliff looms around 2028–29, threatening £2.74bn in H1 2026 sales. Vaccine restructuring cuts 641 Dresden jobs.

    Competitive threats and patent expirations weigh on long-term growth outlook.

September 2026
▲2▼1

GSK pipeline wins and buybacks offset HIV patent cliff and flu competition

  • Specialty Medicines growth and pipeline expansion GSK's Specialty Medicines sales rose 14% in H1 2026, now over 40% of total sales, with double-digit growth in HIV, respiratory, immunology and oncology. The company plans more than 20 late-stage studies in 2026, more than double its original target, supporting long-term revenue growth and lifting the shares.

    This shows the core growth engine that is driving GSK's earnings and share price higher.

  • HIV patent cliff looms GSK faces loss of exclusivity for dolutegravir, the backbone of its HIV medicines, with patents expiring in major markets around 2028-2029. Those products generated £2.74 billion in H1 2026 sales, so the eventual loss of protection threatens a significant revenue stream and weighs on the share price.

    This is a major medium-term risk that could pressure future earnings and investor sentiment.

  • Oncology pipeline boosted by lung cancer data and Chimagen deal GSK rose 4.7% after positive trial results for two lung cancer treatments. It also acquired full global rights to Chimagen's trispecific T-cell engager for multiple myeloma for up to $750 million, expanding its oncology pipeline and reinforcing growth prospects.

    These are concrete pipeline advances that directly lifted the stock and add new oncology assets.

  • Vaccine restructuring and mRNA flu advance GSK will close its Dresden vaccine plant by 2027, cutting 641 jobs, to consolidate flu vaccine production in Canada amid falling demand for egg-based vaccines. At the same time, it advanced its mRNA flu vaccine to Phase III after strong mid-stage results, aiming to defend its flu franchise against new competitors like Moderna.

    This shows GSK cutting costs and investing in next-generation vaccines to offset competitive threats.

Latest
▲2▼1

GSK pipeline wins and buybacks offset HIV patent cliff and flu competition

  • Specialty Medicines growth and pipeline expansion GSK's Specialty Medicines sales rose 14% in H1 2026, now over 40% of total sales, with double-digit growth in HIV, respiratory, immunology and oncology. The company plans more than 20 late-stage studies in 2026, more than double its original target, supporting long-term revenue growth and lifting the shares.

    This shows the core growth engine that is driving GSK's earnings and share price higher.

  • HIV patent cliff looms GSK faces loss of exclusivity for dolutegravir, the backbone of its HIV medicines, with patents expiring in major markets around 2028-2029. Those products generated £2.74 billion in H1 2026 sales, so the eventual loss of protection threatens a significant revenue stream and weighs on the share price.

    This is a major medium-term risk that could pressure future earnings and investor sentiment.

  • Oncology pipeline boosted by lung cancer data and Chimagen deal GSK rose 4.7% after positive trial results for two lung cancer treatments. It also acquired full global rights to Chimagen's trispecific T-cell engager for multiple myeloma for up to $750 million, expanding its oncology pipeline and reinforcing growth prospects.

    These are concrete pipeline advances that directly lifted the stock and add new oncology assets.

  • Vaccine restructuring and mRNA flu advance GSK will close its Dresden vaccine plant by 2027, cutting 641 jobs, to consolidate flu vaccine production in Canada amid falling demand for egg-based vaccines. At the same time, it advanced its mRNA flu vaccine to Phase III after strong mid-stage results, aiming to defend its flu franchise against new competitors like Moderna.

    This shows GSK cutting costs and investing in next-generation vaccines to offset competitive threats.

August 2026
▲3▼1

GSK rises on cost cuts, new drug wins, but Moderna threat looms

  • Cost-savings plan and UK investment GSK announced a £1.9bn cost-savings plan to fund late-stage trials, a £400m UK investment, and a new Cambridge R&D hub. This signals efficiency and commitment to innovation, boosting investor confidence.

    This is a major new financial and strategic initiative that drove shares up.

  • Strong Q2 results and raised sales guidance Q2 profit beat expectations, with sales up 5% to over £8.4bn and raised sales guidance. Although EPS guidance was cut on Nuvalent-related interest costs, the overall beat and sales outlook lifted shares.

    Quarterly earnings are a key driver of stock performance and provided positive surprises.

  • Regulatory wins for Jemperli and Hibsago FDA priority review for Jemperli in rectal cancer and world's first approval of Hibsago, a hepatitis B cure, plus Phase III progress for GSK's mRNA flu vaccine, lifted shares on pipeline strength.

    These regulatory milestones represent new growth opportunities and validate GSK's R&D.

  • Moderna's mRNA flu vaccine threat Moderna's FDA-approved mRNA flu vaccine directly threatens GSK's leading flu franchise, potentially pressuring future sales. This competitive threat is a new headwind for GSK.

    It introduces a significant competitive risk that could undermine a key revenue stream.

▲2▼1

GSK pipeline wins and cost cuts drive gains, Moderna flu threat weighs

  • Jemperli priority review for rectal cancer The FDA accepted GSK's Jemperli for priority review in locally advanced rectal cancer, with a decision expected by February 2027. Positive trial data showed patients had no detectable cancer for at least a year. This raises hopes for a new revenue stream and lifts the shares.

    A new regulatory milestone for a key cancer drug adds to GSK's growth outlook.

  • Moderna's mRNA flu vaccine approval Moderna won FDA approval for the first mRNA flu vaccine, for adults 50 and over, directly challenging GSK's flu vaccine business. While uptake depends on pricing and pharmacy stocking, it introduces a new competitor in a market GSK has long led, which could pressure future sales and the share price.

    This is a competitive threat to GSK's established flu vaccine franchise.

  • Hepatitis B cure and mRNA flu advance GSK won the world's first approval for Hibsago, a functional cure for chronic hepatitis B, in Japan. It also advanced its own mRNA flu vaccine to Phase III after positive mid-stage data. Both are new pipeline wins that could drive long-term growth and support the shares.

    Two separate pipeline successes show GSK's research is delivering new products.

▲4

GSK's cost cuts and pipeline push lift shares despite profit dip

  • £1.9bn savings drive and UK investment GSK launched a three-year £1.9bn cost-savings plan to fund late-stage drug trials and simplify the business, plus a £400m UK investment including a new R&D centre. Shares jumped 4.2% as investors welcomed the plan to protect profits while spending on new drugs.

    This is the main new event that directly moved the share price up and shows management's plan to fund growth.

  • Q2 profit beat and raised sales guidance GSK beat second-quarter profit expectations, with sales up 5% to over £8.4bn and core earnings per share up 9%. It raised full-year sales and operating profit guidance to the upper half of its range, though it lowered EPS guidance due to extra interest costs from the Nuvalent deal.

    The earnings beat and guidance raise are new and directly support the share price, while the EPS cut is a real counterweight.

  • AI drug discovery partnership and Cambridge R&D hub GSK expanded its AI drug discovery collaboration with Relation Therapeutics, worth up to $110m, and announced a new Cambridge R&D hub for over 1,000 scientists. These moves aim to speed up finding new drugs and strengthen GSK's long-term pipeline.

    This is a new strategic step that could improve future growth prospects, though the financial impact is longer-term.

  • Record UK lab space demand from GSK prelet GSK's 300,000-square-foot prelet at Cambridge Biomedical Campus helped push UK lab space demand to a record high. This shows GSK is investing in research capacity, but high lab vacancies and slowing construction are a broader industry caution.

    It confirms GSK's commitment to UK R&D and signals demand for its facilities, a new positive signal for the company's growth plans.

July 2026
▲2▼2

GSK's lung cancer win offset by pipeline setback and legal risk

  • FDA approves first lung cancer drug Jiditro GSK won early FDA approval for Jiditro, its first lung cancer drug, for previously treated ROS1-positive NSCLC. This opens a new high-margin oncology market and supports GSK's goal of over £40bn revenue by 2031, lifting investor confidence.

    This is a major new approval that directly boosts GSK's oncology growth story and revenue outlook.

  • GSK drops chronic cough drug camlipixant GSK stopped developing camlipixant after mixed late-stage trial results, removing a potential £2.5bn-a-year product. Shares fell up to 4.5%. Analysts called it a credibility hit and questioned GSK's acquisition strategy, adding pressure on management.

    This is a fresh pipeline failure that removes a key late-stage asset and hurts sentiment.

  • AnaptysBio lawsuit over Jemperli rights AnaptysBio accuses GSK of violating their commercial agreement for Jemperli. A trial began July 14-17. If AnaptysBio wins, GSK could lose rights to the drug. Even a settlement or acquisition could cost GSK, creating uncertainty.

    This legal risk could threaten a marketed cancer drug and is a new overhang on the stock.

  • Pipeline progress: Ris-Rez and Bexsero Hansoh's Ris-Rez showed survival benefit in lung cancer; GSK holds ex-China rights. EMA accepted a Bexsero label update for a single-dose booster in adolescents. Both support future sales growth and strengthen GSK's vaccine and oncology portfolios.

    These are new positive clinical and regulatory milestones that add to GSK's growth pipeline.

▲2▼2

GSK's lung cancer win offset by pipeline setback and legal risk

  • FDA approves first lung cancer drug Jiditro GSK won early FDA approval for Jiditro, its first lung cancer drug, for previously treated ROS1-positive NSCLC. This opens a new high-margin oncology market and supports GSK's goal of over £40bn revenue by 2031, lifting investor confidence.

    This is a major new approval that directly boosts GSK's oncology growth story and revenue outlook.

  • GSK drops chronic cough drug camlipixant GSK stopped developing camlipixant after mixed late-stage trial results, removing a potential £2.5bn-a-year product. Shares fell up to 4.5%. Analysts called it a credibility hit and questioned GSK's acquisition strategy, adding pressure on management.

    This is a fresh pipeline failure that removes a key late-stage asset and hurts sentiment.

  • AnaptysBio lawsuit over Jemperli rights AnaptysBio accuses GSK of violating their commercial agreement for Jemperli. A trial began July 14-17. If AnaptysBio wins, GSK could lose rights to the drug. Even a settlement or acquisition could cost GSK, creating uncertainty.

    This legal risk could threaten a marketed cancer drug and is a new overhang on the stock.

  • Pipeline progress: Ris-Rez and Bexsero Hansoh's Ris-Rez showed survival benefit in lung cancer; GSK holds ex-China rights. EMA accepted a Bexsero label update for a single-dose booster in adolescents. Both support future sales growth and strengthen GSK's vaccine and oncology portfolios.

    These are new positive clinical and regulatory milestones that add to GSK's growth pipeline.

Q2 2026
▲3▼1

GSK's pipeline and dealmaking drive gains, but tariff risk lingers

  • FDA approval of Utebzi GSK and Spero won FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. This opens a new market and strengthens GSK's anti-infectives portfolio, with launch expected by end-2026.

    This is a concrete regulatory win that directly boosts GSK's revenue prospects.

  • M&A surge and GSK's Nuvalent deal Biopharma M&A hit a six-year high with $65 billion in Q1 deals, and GSK is acquiring Nuvalent for $10.6 billion. This shows GSK is actively filling pipeline gaps, which investors view as a growth signal.

    The Nuvalent acquisition is a major strategic move that addresses pipeline concerns and reflects industry confidence.

  • Physician interest in Benlysta for CTD-ILD A survey shows rheumatologists are highly interested in GSK's Benlysta for CTD-ILD, a condition with few effective treatments. This hints at potential expanded use and future sales growth.

    It points to a possible new indication for an existing GSK drug, which could add revenue.

  • US tariff and policy concerns Industry confidence is high, but 69% of executives cite US tariffs and government actions as the biggest worry, rising to 78% among Europeans. For GSK, a UK-based company, this could mean higher costs or barriers in its largest market.

    It provides a real counterweight to the positive news, highlighting a risk that could pressure the stock.

June 2026
▲3▼1

GSK's pipeline and dealmaking drive gains, but tariff risk lingers

  • FDA approval of Utebzi GSK and Spero won FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. This opens a new market and strengthens GSK's anti-infectives portfolio, with launch expected by end-2026.

    This is a concrete regulatory win that directly boosts GSK's revenue prospects.

  • M&A surge and GSK's Nuvalent deal Biopharma M&A hit a six-year high with $65 billion in Q1 deals, and GSK is acquiring Nuvalent for $10.6 billion. This shows GSK is actively filling pipeline gaps, which investors view as a growth signal.

    The Nuvalent acquisition is a major strategic move that addresses pipeline concerns and reflects industry confidence.

  • Physician interest in Benlysta for CTD-ILD A survey shows rheumatologists are highly interested in GSK's Benlysta for CTD-ILD, a condition with few effective treatments. This hints at potential expanded use and future sales growth.

    It points to a possible new indication for an existing GSK drug, which could add revenue.

  • US tariff and policy concerns Industry confidence is high, but 69% of executives cite US tariffs and government actions as the biggest worry, rising to 78% among Europeans. For GSK, a UK-based company, this could mean higher costs or barriers in its largest market.

    It provides a real counterweight to the positive news, highlighting a risk that could pressure the stock.

▲3▼1

GSK's pipeline and dealmaking drive gains, but tariff risk lingers

  • FDA approval of Utebzi GSK and Spero won FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. This opens a new market and strengthens GSK's anti-infectives portfolio, with launch expected by end-2026.

    This is a concrete regulatory win that directly boosts GSK's revenue prospects.

  • M&A surge and GSK's Nuvalent deal Biopharma M&A hit a six-year high with $65 billion in Q1 deals, and GSK is acquiring Nuvalent for $10.6 billion. This shows GSK is actively filling pipeline gaps, which investors view as a growth signal.

    The Nuvalent acquisition is a major strategic move that addresses pipeline concerns and reflects industry confidence.

  • Physician interest in Benlysta for CTD-ILD A survey shows rheumatologists are highly interested in GSK's Benlysta for CTD-ILD, a condition with few effective treatments. This hints at potential expanded use and future sales growth.

    It points to a possible new indication for an existing GSK drug, which could add revenue.

  • US tariff and policy concerns Industry confidence is high, but 69% of executives cite US tariffs and government actions as the biggest worry, rising to 78% among Europeans. For GSK, a UK-based company, this could mean higher costs or barriers in its largest market.

    It provides a real counterweight to the positive news, highlighting a risk that could pressure the stock.

UK Pound Sterling/US Dollar FX Spot Rate (GBPUSD.FOREX)

Q3 2026
▲1▼1

Fed-BoE Rate Gap and UK Fiscal Worries Drive Sterling

  • Fed-BoE Rate Expectations Sterling first rose on soft US data and hawkish BoE splits, then fell as Fed hike bets grew and the Fed raised rates to 3.75–4.00%, widening the US-UK rate gap.

    This is the main force moving GBP/USD throughout the quarter.

  • UK Political and Fiscal Uncertainty UK political and fiscal worries, including 18-year-high bond yields, weighed on sterling as investors fretted about the government's finances.

    This was a key drag on the pound during the quarter.

  • UK Inflation and BoE Hike Signals UK inflation at 3.1% and BoE hike signals from officials supported sterling, though Bailey and Ramsden downplaying hikes tempered gains.

    This provided support to the pound and is new information.

  • Middle East Tensions and Bank Forecasts Middle East tensions capped sterling's gains, while major bank forecasts supported it, creating a mixed backdrop for the currency.

    These factors added to the mix of influences on GBP/USD.

September 2026
▲2▼1

Fed hike widens rate gap, but BoE hike bets support sterling

  • Fed rate hike widens US-UK rate gap The Fed raised rates to 3.75–4.00%, making dollar deposits more attractive and pressuring the pound by widening the interest rate gap between the US and UK.

    This directly explains a key force pushing GBPUSD down during the period.

  • UK inflation spike and BoE hike signals UK inflation hit 3.1%, above forecast, and the BoE signalled possible hikes with three members voting to raise rates and inflation projected above 4%, supporting sterling.

    This shows a major positive force for the pound from higher expected UK rates.

  • Major banks forecast BoE hikes Barclays, JPMorgan, Goldman Sachs, BofA and Morgan Stanley forecast BoE hikes in November and February, with markets pricing ~75% odds of a November move, boosting sterling.

    This highlights market expectations that drove demand for the pound.

  • BoE officials downplay hike bets Governor Bailey downplayed hike bets and Deputy Governor Ramsden called domestic pressures subdued, creating uncertainty that tempered sterling's gains despite energy-driven inflation.

    This provides a counterweight that limited the pound's upside.

Latest
▲2

BoE hike bets build as energy-driven inflation persists, lifting sterling

  • Bailey pushes back on hike bets, but energy inflation keeps BoE hawkish BoE Governor Bailey said the market's rate curve includes a risk premium and a hike is only one possibility, which briefly weakened the pound. But he also flagged energy-driven inflation risks, and Deputy Governor Ramsden called domestic pressures subdued. The net effect is a tug-of-war, with inflation worries keeping sterling supported.

    Explains the key BoE policy signal that sets the tone for sterling this period.

  • Banks forecast BoE hikes in November and February as energy prices stay high Goldman Sachs, Barclays, JPMorgan, BofA and Morgan Stanley now expect the BoE to raise rates in November and again in February 2027, citing energy-driven inflation. More expected UK rate hikes draw global money into sterling, pushing GBPUSD up. Markets price about a 75% chance of a November hike.

    Shows growing consensus among major banks that UK rates will rise, a key force lifting the pound.

▲3▼1

Fed hikes, BoE signals hike as UK inflation hits 3.1%

  • Fed raises rates to 3.75-4.00%, widening US-UK gap The Fed raised rates by 0.25% to 3.75-4.00%, its first hike since 2023, while the BoE held at 3.75%. Higher US rates attract global money into dollars, so the pound buys fewer dollars and GBPUSD falls.

    This is the main new force pushing GBPUSD down, as the US-UK rate gap widens in the dollar's favor.

  • UK inflation hits 3.1%, keeping BoE rate-cut hopes in check UK inflation rose to a five-month high of 3.1%, above the BoE's 2.8% forecast. This makes near-term rate cuts less likely, supporting sterling by keeping UK interest rates relatively attractive.

    Higher UK inflation reduces the chance of rate cuts, which supports the pound and pushes GBPUSD up.

  • BoE holds at 3.75% but signals possible hike as inflation seen topping 4% The BoE held rates but three members voted to hike and it projected inflation above 4% in early 2027. It also halted bond sales. This hawkish stance makes pound deposits more attractive, pushing GBPUSD up.

    The BoE's hawkish hold and inflation warning support sterling by raising expectations of future UK rate hikes.

  • Barclays and JPMorgan expect BoE hikes in November and February Barclays and JPMorgan now expect the BoE to raise rates in November and again in February 2027, citing energy-driven inflation. More expected UK rate hikes draw money into sterling, pushing GBPUSD up.

    This reinforces the positive rate-differential story for sterling, as major banks forecast further BoE tightening.

August 2026
▼2▲1

Fed and BoE rate hike bets, UK fiscal strain drive sterling

  • Fed rate hike bets strengthen the dollar Fed Chair Warsh said rate hikes may be needed to curb inflation, lifting the chance of a September hike to 57.5% from 35%. Higher US rates attract global money into dollars, so the pound buys fewer dollars and GBPUSD falls.

    This is the main new force pushing GBPUSD down this period.

  • BoE rate hike calls support sterling BoE chief economist Huw Pill said the policy rate needs to rise to 4% to stop war-driven inflation becoming persistent. Higher UK rates make pound deposits more attractive, drawing money into sterling and pushing GBPUSD up.

    This is the main new force pushing GBPUSD up this period.

  • UK fiscal worries and 18-year high bond yields UK 10-year bond yields hit 5.268%, the highest since 2008, forcing the government to plan £11bn of tax rises or spending cuts. Investors worry about UK finances, which can weaken the pound and push GBPUSD down.

    New UK-specific risk weighing on sterling.

  • UK inflation at 2.9% keeps BoE on hold for now UK inflation rose to 2.9% in July, in line with expectations, so most analysts expect the Bank of England to keep rates at 3.75% for now. No immediate rate move means little fresh direction for GBPUSD.

    Explains why the BoE has not yet acted, balancing the rate-hike talk.

▼2▲1

Fed and BoE rate hike bets, UK fiscal strain drive sterling

  • Fed rate hike bets strengthen the dollar Fed Chair Warsh said rate hikes may be needed to curb inflation, lifting the chance of a September hike to 57.5% from 35%. Higher US rates attract global money into dollars, so the pound buys fewer dollars and GBPUSD falls.

    This is the main new force pushing GBPUSD down this period.

  • BoE rate hike calls support sterling BoE chief economist Huw Pill said the policy rate needs to rise to 4% to stop war-driven inflation becoming persistent. Higher UK rates make pound deposits more attractive, drawing money into sterling and pushing GBPUSD up.

    This is the main new force pushing GBPUSD up this period.

  • UK fiscal worries and 18-year high bond yields UK 10-year bond yields hit 5.268%, the highest since 2008, forcing the government to plan £11bn of tax rises or spending cuts. Investors worry about UK finances, which can weaken the pound and push GBPUSD down.

    New UK-specific risk weighing on sterling.

  • UK inflation at 2.9% keeps BoE on hold for now UK inflation rose to 2.9% in July, in line with expectations, so most analysts expect the Bank of England to keep rates at 3.75% for now. No immediate rate move means little fresh direction for GBPUSD.

    Explains why the BoE has not yet acted, balancing the rate-hike talk.

July 2026
▲2▼1

Sterling Rises on Dollar Weakness, Then Falls on UK Political Uncertainty

  • Dollar Weakness Lifts Sterling Soft US jobs and inflation data reduced expectations of Fed rate hikes, weakening the dollar and pushing GBP/USD higher. This was the main driver of sterling's rise over the period.

    It explains the primary force behind the pound's appreciation.

  • Hawkish BoE Split and Firm UK Retail Sales Support Sterling A split Bank of England vote with some officials favoring rate hikes, combined with solid UK retail sales, provided support for the pound by suggesting higher interest rates ahead.

    It highlights domestic factors that bolstered sterling.

  • UK Political and Fiscal Uncertainty Weighs on Pound A surprise Chancellor appointment and broader political uncertainty, along with weak wage growth and cooling UK inflation, dragged the pound lower as investors worried about fiscal policy.

    It identifies key UK-specific negative factors.

  • Middle East Tensions and Fed Rate Hold Create Mixed Dollar Impact Middle East tensions revived safe-haven dollar demand, capping sterling's gains, but later the Fed's rate hold and Iran diplomacy hopes weakened the dollar, lifting GBP/USD. Bailey's pushback against hikes limited further upside.

    It captures the opposing forces that influenced the dollar and thus GBP/USD.

▲3

Bank of England's hawkish split lifts pound; Fed hold and Iran diplomacy weaken dollar

  • Bank of England holds rates but three members vote for a hike The Bank of England kept its main rate at 3.75% on July 30, but three of nine officials voted to raise it, up from two before. That hawkish split makes traders think UK rates may rise sooner, which attracts money into the pound and pushes GBPUSD up.

    This is the period's biggest new UK event and directly lifts the pound via higher expected UK rates.

  • Federal Reserve holds rates, dollar falls broadly The Fed left US rates unchanged for a fifth straight meeting on July 29, with only three of twelve officials wanting a hike. When US rate rises look less likely, the dollar loses appeal, so each pound buys more dollars and GBPUSD rises.

    A new Fed decision that weakens the dollar is a core driver of GBPUSD this period.

  • Iran diplomacy hopes and suspected yen intervention weaken the dollar Fresh hopes for Iran talks and suspected Japanese intervention to support the yen knocked the US dollar lower across many currencies. A broadly weaker dollar lifts GBPUSD, helping the pound recover from a three-week low early in the period.

    New geopolitical and currency-intervention news that weakened the dollar, supporting GBPUSD.

  • UK inflation seen above target for years, but Bailey pushes back on hikes Forecaster NIESR said UK inflation will stay above 2% until 2029, and BoE's Pill warned energy prices could feed longer-term inflation, supporting the pound. But Governor Bailey said he is not leaning toward rate hikes, a counterweight that limits GBPUSD gains.

    Shows both the new inflation-risk support for the pound and the governor's pushback that caps it.

▼3▲1

UK political and fiscal uncertainty drags pound; soft data and safe-haven dollar add pressure

  • New UK Chancellor appointment sparks fiscal worries, weakening pound John Healey became Chancellor in a surprise move, pushing UK borrowing costs to a two-month high and the pound down to $1.341. Investors worry the new government will borrow more, making the pound less attractive and pushing GBPUSD lower.

    This is a new political event that directly weakens sterling by raising fiscal uncertainty.

  • UK wage growth stays weak, reducing pressure for Bank of England rate hikes Average wages excluding bonuses rose only 3.4% year-on-year, the lowest since 2020, and private-sector wage growth was just 2.9%. With little inflation pressure from pay, the Bank of England is expected to keep rates at 3.75%, making the pound less appealing versus the dollar.

    Weak wage data lowers expectations for UK rate hikes, a key negative for GBPUSD.

  • UK inflation slows more than expected, easing pressure on Bank of England UK inflation fell to 2.6% in June, below the 2.7% forecast, the slowest in 15 months. This reduces the chance of Bank of England rate hikes, weakening the pound against the dollar as investors see less reason to hold sterling.

    Lower inflation reduces the case for higher UK rates, a direct negative for GBPUSD.

  • UK retail sales unexpectedly grow, giving pound a small lift UK retail sales rose 1.0% in June, beating forecasts of a 0.3% decline. The surprise strength in consumer spending supports the pound, showing the economy is holding up despite political uncertainty, which helps GBPUSD.

    This is a new positive data point that supports sterling and counters some negative drivers.

▲2▼2

US inflation cools, Fed hike bets fade; BoE hike bets rise, lifting pound

  • Soft US inflation data weakens the dollar US consumer and wholesale inflation slowed in June, so traders cut the chance of a July Fed rate hike to 16% from 42%. When US rate-rise bets fade, the dollar usually weakens, lifting GBPUSD because each pound buys more dollars. The pound jumped to $1.3554, its highest since mid-May.

    This is the main new force pushing GBPUSD up this period.

  • BoE rate-hike bets strengthen sterling Investors now fully price a Bank of England rate hike in September and about two quarter-point hikes by December, pushing UK two-year gilt yields to their highest since May. Higher expected UK rates make the pound more attractive to hold, supporting GBPUSD. Reduced UK political uncertainty adds to the pound's appeal.

    Rising UK rate expectations are a key new support for the pound.

  • Middle East war revives safe-haven dollar demand Iran and the US exchanged intensifying fire, Iran claimed it closed the Strait of Hormuz, and oil hit near one-month highs. In uncertain times money flows to the US dollar as a safe haven, pushing GBPUSD down. The pound dipped below $1.34 on July 13 before recovering.

    This is the main new counterweight capping the pound's gains.

  • BoE deputy says war is the only inflation problem Deputy Governor Breeden said UK inflation would already be at the 2% target without the Middle East war. That hints the Bank of England may need fewer rate hikes once the war's oil-price effect fades, trimming support for the pound. It is a modest drag on GBPUSD.

    It is a new signal that could reduce future BoE rate support for sterling.

▲3▼1

Weak US jobs data and fading Fed hike bets lift pound; Middle East tensions cap gains

  • Weak US jobs data dents Fed rate-hike bets, weakening the dollar US employers added only 57,000 jobs in June, far below the 110,000 expected. That made traders doubt the Federal Reserve will raise interest rates soon. When US rate-rise bets fade, the dollar usually weakens, which lifts GBPUSD because each pound buys more dollars.

    This is the main new force pushing GBPUSD up this period.

  • Fed hike odds fall further as jobless claims stay steady Weekly US jobless claims were steady, and the market-implied chance of a July Fed rate hike dropped to about 26%. Lower odds of higher US rates reduce the dollar's appeal, supporting GBPUSD. The pound rose to around $1.3415 as the dollar fell for a second day.

    Shows the Fed rate-hike story is fading, a key new driver for the pound.

  • Middle East tensions revive safe-haven dollar demand Attacks on ships in the Strait of Hormuz and Trump saying the Iran ceasefire is over made investors nervous. In uncertain times, money often flows to the US dollar as a safe haven, which pushes GBPUSD down. The pound dipped below $1.3350 on July 6 before recovering.

    This is the main new counterweight capping the pound's gains.

  • UK factory data improves, giving sterling a small lift An upward revision to UK factory PMI data supported the pound, helping it rise against the dollar. Stronger UK economic signals can make the pound more attractive to investors, adding to GBPUSD gains. This is a modest but new positive for sterling.

    A new UK-specific positive that adds to the pound's support.

Q2 2026
▼4

Sterling Tumbles on Hawkish Fed, UK Political Turmoil

  • Hawkish Fed Lifts Dollar The Federal Reserve turned hawkish, signalling possible rate hikes that pushed the dollar to a 13-month high. A stronger dollar makes sterling weaker by comparison, as investors seek higher-yielding US assets.

    This is a primary driver of sterling weakness, as a stronger dollar directly lowers GBPUSD.

  • BoE Holds Rates, Warns on Inflation The Bank of England kept interest rates at 3.75% and warned inflation would exceed 3.25%. This gave the pound no support, as higher rates typically attract foreign capital and boost a currency.

    The BoE's inaction and inflation warning removed a potential support for sterling, contributing to its decline.

  • UK Political Turmoil Spooks Investors Andy Burnham's by-election win, fiscal loosening fears, and Keir Starmer's resignation rattled markets. Gilt yields rose to 4.81% and GBPUSD hit a seven-month low near $1.314, as political uncertainty weighed on sterling.

    Political instability directly undermined confidence in UK assets, driving sterling to multi-month lows.

  • Goldman Sachs Flags Sterling Overvalued Goldman Sachs identified sterling as the most overvalued G10 currency, citing Brexit drag and a soft BoE as medium-term headwinds. This reinforced bearish sentiment and encouraged selling of the pound.

    A major bank's warning added to negative sentiment, pressuring sterling further.

June 2026
▼4

Sterling Tumbles on Hawkish Fed, UK Political Turmoil

  • Hawkish Fed Lifts Dollar The Federal Reserve turned hawkish, signalling possible rate hikes that pushed the dollar to a 13-month high. A stronger dollar makes sterling weaker by comparison, as investors seek higher-yielding US assets.

    This is a primary driver of sterling weakness, as a stronger dollar directly lowers GBPUSD.

  • BoE Holds Rates, Warns on Inflation The Bank of England kept interest rates at 3.75% and warned inflation would exceed 3.25%. This gave the pound no support, as higher rates typically attract foreign capital and boost a currency.

    The BoE's inaction and inflation warning removed a potential support for sterling, contributing to its decline.

  • UK Political Turmoil Spooks Investors Andy Burnham's by-election win, fiscal loosening fears, and Keir Starmer's resignation rattled markets. Gilt yields rose to 4.81% and GBPUSD hit a seven-month low near $1.314, as political uncertainty weighed on sterling.

    Political instability directly undermined confidence in UK assets, driving sterling to multi-month lows.

  • Goldman Sachs Flags Sterling Overvalued Goldman Sachs identified sterling as the most overvalued G10 currency, citing Brexit drag and a soft BoE as medium-term headwinds. This reinforced bearish sentiment and encouraged selling of the pound.

    A major bank's warning added to negative sentiment, pressuring sterling further.

▼2▲1

UK political crisis and Fed rate-hike bets push pound to seven-month low

  • Starmer resignation triggers political uncertainty Keir Starmer resigned as Prime Minister, making way for a seventh UK leader in a decade. Sterling fell near its 2026 low as investors worried about fiscal loosening under likely successor Andy Burnham. Political instability makes the pound less attractive, pushing GBPUSD down.

    This is the main new political shock this period and directly weakens sterling.

  • Fed rate-hike bets lift dollar to 13-month high Traders now expect the Federal Reserve to raise rates as soon as October, with a 50/50 chance of a second hike by year-end. The dollar hit a 13-month high, making it stronger versus the pound and pushing GBPUSD to a seven-month low of $1.314.

    This is the dominant monetary force driving the dollar side of the pair.

  • BoE eases stablecoin rules, supporting sterling demand The Bank of England scrapped a planned cap on stablecoin holdings and relaxed backing rules, allowing up to 70% of reserves in short-term government debt. This could boost sterling-backed stablecoin adoption and create fresh demand for the pound, a small counterweight to the negative drivers.

    It is a new regulatory change that could support GBP demand, offering a fair counterbalance.

▼4

Sterling falls as Fed turns hawkish and UK political risk rises

  • Fed signals possible rate hike, lifting the dollar The Federal Reserve held rates but nine of 19 officials now expect a hike by year-end, pushing the dollar to a 13-month high. A stronger dollar means it takes fewer dollars to buy one pound, so GBPUSD falls.

    This is the main new force driving the dollar side of the pair.

  • Bank of England holds rates but warns inflation will rise The BoE kept its key rate at 3.75%, with two members voting for a hike. It warned inflation will climb above 3.25% later this year due to the Iran war. No cut soon means no extra support for the pound.

    The BoE decision is a key new event for the pound side of the pair.

  • UK political turmoil and spending fears hit sterling Andy Burnham's by-election win raised fears of looser fiscal rules and higher borrowing. UK 10-year gilt yields rose to 4.81%, and the pound fell below $1.32 to a two-month low as investors worried about political uncertainty.

    This is a new political shock that directly weakens the pound.

  • Goldman Sachs says sterling is the most overvalued G10 currency Goldman warned that the pound's post-Brexit recovery has overshot, leaving it the most overvalued major currency. It cited Brexit's drag on fair value and a relatively soft Bank of England as medium-term headwinds, suggesting less room for further gains.

    This adds a new fundamental valuation headwind for the pound.

© 2026 MarketIVWhy